<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03245619</url>
  </required_header>
  <id_info>
    <org_study_id>201570</org_study_id>
    <secondary_id>2016-001303-22</secondary_id>
    <nct_id>NCT03245619</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults</brief_title>
  <official_title>Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous Bolus) and Constant Intravenous Infusion Over 7 Days of GSK3335065 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of&#xD;
      reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them&#xD;
      at this level throughout the treatment period. This study will utilize an adaptive design and&#xD;
      is divided into 3 parts. Part A will consist of 8 cohorts (1-8) and is Single Ascending Dose&#xD;
      (SAD) of GSK3335065 by IV bolus in males. Part B will be initiated after completion of dosing&#xD;
      in Part A. It will involve ascending IV bolus doses of GSK3335065 followed by IV constant&#xD;
      infusion for 7 days in males and will consist of four cohorts (9-12). Part C consists of a&#xD;
      single dose of GSK3335065 by IV bolus (cohort 13), and a single dose followed by continuous&#xD;
      infusion over 7 days (cohort 14) in females of non-child bearing potential (WONCBP). Total 64&#xD;
      subjects will be evaluated in the study of which Part A will include 16 healthy male&#xD;
      subjects, Part B will include 32 healthy male subjects and Part C will include 16 WONCBP. In&#xD;
      Part A, cohorts 1 and 2 will last up to 19 weeks and cohorts 3 to 8 will last up to 7 weeks&#xD;
      and Part B will last up to 13 weeks. In Part C cohort 7 will last up to 7 weeks and cohort 8&#xD;
      will last for 13 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated as relationship between GSK3335065 and ventricular tachycardia could&#xD;
    not be excluded.&#xD;
  </why_stopped>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Actual">May 19, 2018</completion_date>
  <primary_completion_date type="Actual">May 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. All Subject Population comprised of all participants randomized to treatment who received at least one dose of study treatment. AEs and SAEs were collected from admission until follow-up. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs and SAEs-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs and SAEs-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells per liter [cells/L]); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells count (low: &lt;3x10^9 cells/L and high: &gt;20x10^9 cells/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: albumin (low: &lt;30 millimoles per liter [mmol/L]); alanine aminotransferase (ALT) (high: &gt;=2xupper limit of normal [ULN]); aspartate aminotransferase (AST) (high: &gt;=2xULN); alkaline phosphatase (ALP) (high: &gt;=2xULN); total bilirubin (high: &gt;=1.5xULN); calcium (low: &lt;2 mmol/L and high: &gt;2.75 mmol/L); glucose (low: &lt;3 mmol/L and high: &gt;9 mmol/L); potassium (low: &lt;3 mmol/L and high: &gt;5.5 mmol/L) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urine Parameters-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Urine samples were taken for the assessment of following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed and collected for any abnormal dipstick results. Number of participants with abnormal urine parameters any time post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urine Parameters-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urine Parameters-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QT interval corrected using Fridericia's formula (QTcF) and Bazett's QT interval corrected for heart rate (QTcB). ECG measurements were preceded by at least 5 minutes rest for the participant in a semi-recumbent position. Number of participants with abnormal-clinically significant and abnormal-not clinically significant ECG findings at worst case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs-Part A</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, respiration rate and temperature were measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Participants are counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Data for worst case post-Baseline relative to Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs-Part B</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs-Part C</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for pharmacokinetic (PK) analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. PK Parameter Population comprised of all active participants whose PK sample was obtained and analyzed and who provided PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) for GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) for GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) for GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-Inf) for GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-Inf) for GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-Inf) for GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution for GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution for GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution for GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 for GSK3335065-Part A (Cohorts 3 to 8)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 for GSK3335065-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 for GSK3335065-Part C (Cohort 13)</measure>
    <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 for GSK3335065-Part C (Cohort 14)</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
    <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)</measure>
    <time_frame>Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
    <description>Blood samples were collected to measure the kynurenine-3-monooxygenase (KMO) enzyme inhibition by determining the levels of the biomarkers Kynurenine (Kyn) and 3-hydroxykynurenine (3-HK). Baseline was the average of all pre-dose measurements (Day 1 [pre-dose at 1 hour and 30 minutes]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)</measure>
    <time_frame>Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
    <description>Blood samples were collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK. Baseline was the average of all pre-dose measurements (Day -1 [pre-dose at 16 hours, 14 hours, 12 hours and 10 hours] and Day 1 [pre-dose at 30 minutes and 2 hours]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Tryptophan Metabolites-Part B</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)</time_frame>
    <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Tryptophan Metabolites-Part C</measure>
    <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)</time_frame>
    <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pancreatitis, Acute Necrotizing</condition>
  <arm_group>
    <arm_group_label>Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving Placebo (Cohorts 1 to 8) in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving Placebo (Cohort 9 to 12) in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 13) in Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving Placebo (Cohort 13) in Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 14) in Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving Placebo (Cohort 14) in Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3335065</intervention_name>
    <description>GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.</description>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 13) in Part C</arm_group_label>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 14) in Part C</arm_group_label>
    <arm_group_label>Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B</arm_group_label>
    <arm_group_label>Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.</description>
    <arm_group_label>Subjects receiving Placebo (Cohort 13) in Part C</arm_group_label>
    <arm_group_label>Subjects receiving Placebo (Cohort 14) in Part C</arm_group_label>
    <arm_group_label>Subjects receiving Placebo (Cohort 9 to 12) in Part B</arm_group_label>
    <arm_group_label>Subjects receiving Placebo (Cohorts 1 to 8) in Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects must be 18 to 50 years of age inclusive, at the time of signing the informed&#xD;
             consent. In Part C (WONCBP) subjects must be between 18 and 60 years of age.&#xD;
&#xD;
          -  Subjects who are overtly healthy as determined by medical evaluation including medical&#xD;
             history, physical examination, laboratory tests, and cardiac monitoring.&#xD;
&#xD;
          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not&#xD;
             specifically listed in the inclusion or exclusion criteria, outside the reference&#xD;
             range for the population being studied may be included only if the investigator in&#xD;
             consultation with the Medical Monitor if required agree and document that the finding&#xD;
             is unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Body weight greater than 50 kilogram (kg) and body mass index (BMI) within the range&#xD;
             18.5 - 32 kilogram per meter square (kg/m^2).&#xD;
&#xD;
          -  Length of time required for abstinence or use of contraceptives should take into&#xD;
             account the reproductive toxicity profile including genotoxicity and teratogenicity,&#xD;
             the size of the molecule, and the number of doses. Male subjects must agree to use&#xD;
             contraception during the treatment period and for at least 2 days after the last dose&#xD;
             of study treatment and refrain from donating sperm during this period. Only female&#xD;
             subjects of WONCBP are eligible to participate.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  ALT and bilirubin greater than 1.5 times upper limit of normal (ULN) (isolated&#xD;
             bilirubin greater than 1.5 times ULN is acceptable if bilirubin is fractionated and&#xD;
             direct bilirubin less than 35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          -  QTc corrected by Fridericia's formula(QTcF) greater than 450 millisecond (msec) from a&#xD;
             mean of triplicate readings taken 5 mins apart&#xD;
&#xD;
          -  Clinically significant abnormal echocardiogram&#xD;
&#xD;
          -  The subject has a history or current evidence of depression, bipolar disorder,&#xD;
             suicidal ideation and behavior, or a lifetime history of suicide attempt&#xD;
&#xD;
          -  Cardiac troponin (cTn) or Brain natriuretic peptide (BNP) greater than ULN&#xD;
&#xD;
          -  Use of prohibited medication&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test&#xD;
             result at screening or within 3 months prior to first dose of study treatment. For&#xD;
             potent immunosuppressive agents, subjects with presence of hepatitis B core antibody&#xD;
             (HBcAb) should also be excluded.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliter (mL) within 84 days.&#xD;
&#xD;
          -  Poor or unsuitable venous access&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of &gt;14 units. One unit is equivalent to 8 gram of alcohol: a&#xD;
             half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or Medical&#xD;
             Monitor, contraindicates their participation.&#xD;
&#xD;
          -  History of smoking within 6 months of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <results_first_submitted>June 17, 2019</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>3-hydroxykynurenine</keyword>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>GSK3335065</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Acute Necrotizing</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03245619/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03245619/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was planned to be a 3 part, dose escalation study; however, the study was terminated during Part A (Cohort 3) because a relationship between GSK3335065 and ventricular tachycardia in a participant could not be excluded. Hence, participants were not recruited in Cohorts 4 to 8 of Part A; Part B and Part C were not initiated.</recruitment_details>
      <pre_assignment_details>A total of 55 participants were screened of which 33 failed screening and 4 were kept in reserve but not used. A total of 18 participants were enrolled in the study. The study was conducted in the United Kingdom. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Placebo</title>
          <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
        </group>
        <group group_id="P6">
          <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
        </group>
        <group group_id="P7">
          <title>Part A-Cohort 6: GSK335065 12 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
        </group>
        <group group_id="P8">
          <title>Part A-Cohort 7: GSK335065 35 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
        </group>
        <group group_id="P9">
          <title>Part A-Cohort 8: GSK335065 54 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
        </group>
        <group group_id="P10">
          <title>Part B: Placebo</title>
          <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
        </group>
        <group group_id="P11">
          <title>Part B-Cohort 9: 0.14 mg IV Bolus+0.012 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.012 mg/hour for 7 days.</description>
        </group>
        <group group_id="P12">
          <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
        </group>
        <group group_id="P13">
          <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="P14">
          <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="P15">
          <title>Part C: Placebo</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
        </group>
        <group group_id="P16">
          <title>Part C-Cohort 13: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
        </group>
        <group group_id="P17">
          <title>Part C-Cohort 14: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Up to Day 22)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Up to 34 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C (Up to 34 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated during Part A-Cohort 3; hence, no participants were enrolled in Part A (Cohorts 4 to 8), Part B and Part C.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
        </group>
        <group group_id="B6">
          <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
        </group>
        <group group_id="B7">
          <title>Part A-Cohort 6: GSK335065 12 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
        </group>
        <group group_id="B8">
          <title>Part A-Cohort 7: GSK335065 35 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
        </group>
        <group group_id="B9">
          <title>Part A-Cohort 8: GSK335065 54 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
        </group>
        <group group_id="B10">
          <title>Part B: Placebo</title>
          <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
        </group>
        <group group_id="B11">
          <title>Part B-Cohort 9: 0.14 mg IV Bolus+0.012 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.012 mg/hour for 7 days.</description>
        </group>
        <group group_id="B12">
          <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
        </group>
        <group group_id="B13">
          <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="B14">
          <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="B15">
          <title>Part C: Placebo</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
        </group>
        <group group_id="B16">
          <title>Part C-Cohort 13: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
        </group>
        <group group_id="B17">
          <title>Part C-Cohort 14: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="0"/>
            <count group_id="B11" value="0"/>
            <count group_id="B12" value="0"/>
            <count group_id="B13" value="0"/>
            <count group_id="B14" value="0"/>
            <count group_id="B15" value="0"/>
            <count group_id="B16" value="0"/>
            <count group_id="B17" value="0"/>
            <count group_id="B18" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="5.97"/>
                    <measurement group_id="B2" value="35.8" spread="11.81"/>
                    <measurement group_id="B3" value="43.2" spread="7.57"/>
                    <measurement group_id="B4" value="47.0" spread="NA">Standard deviation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="B18" value="40.6" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>African American/African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. All Subject Population comprised of all participants randomized to treatment who received at least one dose of study treatment. AEs and SAEs were collected from admission until follow-up. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. All Subject Population comprised of all participants randomized to treatment who received at least one dose of study treatment. AEs and SAEs were collected from admission until follow-up. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs and SAEs-Part B</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs and SAEs-Part B</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs and SAEs-Part C</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs and SAEs-Part C</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A</title>
        <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells per liter [cells/L]); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells count (low: &lt;3x10^9 cells/L and high: &gt;20x10^9 cells/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A</title>
          <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells per liter [cells/L]); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells count (low: &lt;3x10^9 cells/L and high: &gt;20x10^9 cells/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B</title>
        <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B</title>
          <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C</title>
        <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C</title>
          <description>Blood samples were planned to be collected for the assessment of hematology parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: albumin (low: &lt;30 millimoles per liter [mmol/L]); alanine aminotransferase (ALT) (high: &gt;=2xupper limit of normal [ULN]); aspartate aminotransferase (AST) (high: &gt;=2xULN); alkaline phosphatase (ALP) (high: &gt;=2xULN); total bilirubin (high: &gt;=1.5xULN); calcium (low: &lt;2 mmol/L and high: &gt;2.75 mmol/L); glucose (low: &lt;3 mmol/L and high: &gt;9 mmol/L); potassium (low: &lt;3 mmol/L and high: &gt;5.5 mmol/L) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: albumin (low: &lt;30 millimoles per liter [mmol/L]); alanine aminotransferase (ALT) (high: &gt;=2xupper limit of normal [ULN]); aspartate aminotransferase (AST) (high: &gt;=2xULN); alkaline phosphatase (ALP) (high: &gt;=2xULN); total bilirubin (high: &gt;=1.5xULN); calcium (low: &lt;2 mmol/L and high: &gt;2.75 mmol/L); glucose (low: &lt;3 mmol/L and high: &gt;9 mmol/L); potassium (low: &lt;3 mmol/L and high: &gt;5.5 mmol/L) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B</title>
        <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B</title>
          <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C</title>
        <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C</title>
          <description>Blood samples were planned to be collected for the assessment of clinical chemistry parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urine Parameters-Part A</title>
        <description>Urine samples were taken for the assessment of following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed and collected for any abnormal dipstick results. Number of participants with abnormal urine parameters any time post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urine Parameters-Part A</title>
          <description>Urine samples were taken for the assessment of following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed and collected for any abnormal dipstick results. Number of participants with abnormal urine parameters any time post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urine Parameters-Part B</title>
        <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urine Parameters-Part B</title>
          <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urine Parameters-Part C</title>
        <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urine Parameters-Part C</title>
          <description>Urine samples were planned to be collected for the assessment of urine parameters.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A</title>
        <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QT interval corrected using Fridericia's formula (QTcF) and Bazett's QT interval corrected for heart rate (QTcB). ECG measurements were preceded by at least 5 minutes rest for the participant in a semi-recumbent position. Number of participants with abnormal-clinically significant and abnormal-not clinically significant ECG findings at worst case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A</title>
          <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QT interval corrected using Fridericia's formula (QTcF) and Bazett's QT interval corrected for heart rate (QTcB). ECG measurements were preceded by at least 5 minutes rest for the participant in a semi-recumbent position. Number of participants with abnormal-clinically significant and abnormal-not clinically significant ECG findings at worst case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal-not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal ECG Findings-Part B</title>
        <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings-Part B</title>
          <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal ECG Findings-Part C</title>
        <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings-Part C</title>
          <description>Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs-Part A</title>
        <description>Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, respiration rate and temperature were measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Participants are counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Data for worst case post-Baseline relative to Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O8">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O9">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs-Part A</title>
          <description>Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, respiration rate and temperature were measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Participants are counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Data for worst case post-Baseline relative to Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; To Normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; To Normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate; To Normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiration rate; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiration rate; To Normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiration rate; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature; To Normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs-Part B</title>
        <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs-Part B</title>
          <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs-Part C</title>
        <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
        <time_frame>Up to Day 34</time_frame>
        <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs-Part C</title>
          <description>Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
          <population>All Subjects Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for pharmacokinetic (PK) analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. PK Parameter Population comprised of all active participants whose PK sample was obtained and analyzed and who provided PK parameters.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for pharmacokinetic (PK) analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. PK Parameter Population comprised of all active participants whose PK sample was obtained and analyzed and who provided PK parameters.</description>
          <population>PK Parameter Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1222" spread="576.3"/>
                    <measurement group_id="O2" value="201.1366" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2701.9080" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) for GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) for GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) for GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) for GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) for GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) for GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
          <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.68" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.</measurement>
                    <measurement group_id="O2" value="310.46" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2811.51" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-Inf) for GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-Inf) for GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-Inf) for GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-Inf) for GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-Inf) for GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-Inf) for GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0006" lower_limit="0.333" upper_limit="71.700"/>
                    <measurement group_id="O2" value="72.0250" lower_limit="72.000" upper_limit="72.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast of GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast of GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.0000" lower_limit="168.000" upper_limit="168.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast of GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast of GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast of GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast of GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast of GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast of GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.018" spread="145.8"/>
                    <measurement group_id="O2" value="14.254" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.090" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2050" lower_limit="0.200" upper_limit="0.500"/>
                    <measurement group_id="O2" value="0.2061" lower_limit="0.200" upper_limit="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2000" lower_limit="0.200" upper_limit="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
          <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9349" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="0.8053" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance for GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance for GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4624" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance for GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance for GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance for GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance for GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance for GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance for GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
          <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.074" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="44.642" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.574" spread="NA">Geometric coefficient of variation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution for GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution for GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution for GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.</description>
          <population>PK Parameter Population. Only participants with PK parameters that could be derived are summarized.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.515" lower_limit="0.515" upper_limit="0.515"/>
                    <measurement group_id="O2" value="34.4957" lower_limit="31.458" upper_limit="49.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 for GSK3335065-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 for GSK3335065-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.265" lower_limit="31.265" upper_limit="31.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 for GSK3335065-Part B</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 for GSK3335065-Part B</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 for GSK3335065-Part C (Cohort 13)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 for GSK3335065-Part C (Cohort 13)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 for GSK3335065-Part C (Cohort 14)</title>
        <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)</time_frame>
        <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 for GSK3335065-Part C (Cohort 14)</title>
          <description>Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.</description>
          <population>PK Parameter Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)</title>
        <description>Blood samples were collected to measure the kynurenine-3-monooxygenase (KMO) enzyme inhibition by determining the levels of the biomarkers Kynurenine (Kyn) and 3-hydroxykynurenine (3-HK). Baseline was the average of all pre-dose measurements (Day 1 [pre-dose at 1 hour and 30 minutes]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
        <time_frame>Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose</time_frame>
        <population>All Subject Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). Data was not collected for placebo arms of Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 1: Placebo</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 2: Placebo</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)</title>
          <description>Blood samples were collected to measure the kynurenine-3-monooxygenase (KMO) enzyme inhibition by determining the levels of the biomarkers Kynurenine (Kyn) and 3-hydroxykynurenine (3-HK). Baseline was the average of all pre-dose measurements (Day 1 [pre-dose at 1 hour and 30 minutes]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
          <population>All Subject Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). Data was not collected for placebo arms of Cohorts 1 and 2.</population>
          <units>Arbitrary units</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-HK, 6 minutes, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5268" lower_limit="-3.424" upper_limit="5.256"/>
                    <measurement group_id="O2" value="-1.5010" lower_limit="-4.173" upper_limit="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 15 minutes, n=5, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9925" lower_limit="-10.193" upper_limit="2.797"/>
                    <measurement group_id="O2" value="-2.0095" lower_limit="-13.189" upper_limit="0.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 30 minutes, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1905" lower_limit="-3.042" upper_limit="0.913"/>
                    <measurement group_id="O2" value="-4.0610" lower_limit="-8.311" upper_limit="-2.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 1 hour, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9763" lower_limit="-9.010" upper_limit="0.786"/>
                    <measurement group_id="O2" value="-4.8000" lower_limit="-53.661" upper_limit="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 1.5 hours, n=5, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1825" lower_limit="-7.525" upper_limit="0.771"/>
                    <measurement group_id="O2" value="-3.7645" lower_limit="-53.469" upper_limit="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 2 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6308" lower_limit="-16.142" upper_limit="-0.428"/>
                    <measurement group_id="O2" value="-2.9960" lower_limit="-53.131" upper_limit="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 3 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2058" lower_limit="-23.589" upper_limit="-0.564"/>
                    <measurement group_id="O2" value="-5.1320" lower_limit="-54.303" upper_limit="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 4.5 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4485" lower_limit="-16.900" upper_limit="0.630"/>
                    <measurement group_id="O2" value="-1.6475" lower_limit="-52.847" upper_limit="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 6 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8595" lower_limit="-14.023" upper_limit="0.955"/>
                    <measurement group_id="O2" value="-1.1470" lower_limit="-54.156" upper_limit="0.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 9 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3513" lower_limit="-15.815" upper_limit="7.477"/>
                    <measurement group_id="O2" value="-1.4675" lower_limit="-52.799" upper_limit="-0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 12 hours, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2715" lower_limit="-11.930" upper_limit="2.690"/>
                    <measurement group_id="O2" value="-6.7390" lower_limit="-51.888" upper_limit="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 15 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0638" lower_limit="-7.953" upper_limit="8.618"/>
                    <measurement group_id="O2" value="-6.3450" lower_limit="-51.817" upper_limit="3.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 18 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5473" lower_limit="-0.393" upper_limit="9.068"/>
                    <measurement group_id="O2" value="-7.0860" lower_limit="-50.969" upper_limit="3.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 24 hours, n=5, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0925" lower_limit="-0.482" upper_limit="30.033"/>
                    <measurement group_id="O2" value="-6.2475" lower_limit="-52.873" upper_limit="3.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 30 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0473" lower_limit="-0.992" upper_limit="53.074"/>
                    <measurement group_id="O2" value="-6.3505" lower_limit="-52.427" upper_limit="6.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 36 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3745" lower_limit="-0.669" upper_limit="29.479"/>
                    <measurement group_id="O2" value="-7.8850" lower_limit="-53.757" upper_limit="-1.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 42 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3905" lower_limit="-1.433" upper_limit="38.095"/>
                    <measurement group_id="O2" value="-7.6030" lower_limit="-53.889" upper_limit="-2.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 48 hours, n=5, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0095" lower_limit="-0.369" upper_limit="61.652"/>
                    <measurement group_id="O2" value="-7.1525" lower_limit="-53.577" upper_limit="-0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 60 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0725" lower_limit="-0.122" upper_limit="65.258"/>
                    <measurement group_id="O2" value="-6.8810" lower_limit="-48.751" upper_limit="-2.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-HK, 72 hours, n=5, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7515" lower_limit="-0.230" upper_limit="82.210"/>
                    <measurement group_id="O2" value="-6.9270" lower_limit="-53.175" upper_limit="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 6 minutes, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.163" lower_limit="-152.30" upper_limit="122.87"/>
                    <measurement group_id="O2" value="-84.808" lower_limit="-190.62" upper_limit="26.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 15 minutes, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.635" lower_limit="-97.53" upper_limit="142.32"/>
                    <measurement group_id="O2" value="-62.958" lower_limit="-242.02" upper_limit="54.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 30 minutes, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.833" lower_limit="-26.27" upper_limit="282.72"/>
                    <measurement group_id="O2" value="-133.385" lower_limit="-189.31" upper_limit="-3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 1 hour, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.555" lower_limit="-58.40" upper_limit="85.20"/>
                    <measurement group_id="O2" value="-177.145" lower_limit="-326.12" upper_limit="156.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 1.5 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.643" lower_limit="-49.59" upper_limit="208.52"/>
                    <measurement group_id="O2" value="-11.232" lower_limit="-330.43" upper_limit="268.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 2 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.290" lower_limit="-127.79" upper_limit="752.12"/>
                    <measurement group_id="O2" value="-12.068" lower_limit="-342.19" upper_limit="300.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 3 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.270" lower_limit="-112.74" upper_limit="175.03"/>
                    <measurement group_id="O2" value="-26.503" lower_limit="-217.56" upper_limit="322.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 4.5 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.150" lower_limit="-299.63" upper_limit="82.56"/>
                    <measurement group_id="O2" value="20.593" lower_limit="-267.84" upper_limit="217.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 6 hours, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.575" lower_limit="-116.56" upper_limit="39.07"/>
                    <measurement group_id="O2" value="-60.595" lower_limit="-226.92" upper_limit="62.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 9 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.120" lower_limit="-142.45" upper_limit="37.49"/>
                    <measurement group_id="O2" value="-20.343" lower_limit="-182.12" upper_limit="104.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 12 hours, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.010" lower_limit="-212.82" upper_limit="5.69"/>
                    <measurement group_id="O2" value="-73.645" lower_limit="-249.04" upper_limit="98.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 15 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.860" lower_limit="-183.49" upper_limit="1.43"/>
                    <measurement group_id="O2" value="49.052" lower_limit="-176.83" upper_limit="293.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 18 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.000" lower_limit="-116.91" upper_limit="27.75"/>
                    <measurement group_id="O2" value="-20.368" lower_limit="-249.38" upper_limit="317.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 24 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.217" lower_limit="-322.14" upper_limit="265.51"/>
                    <measurement group_id="O2" value="30.267" lower_limit="-145.39" upper_limit="302.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 30 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.158" lower_limit="-372.49" upper_limit="221.45"/>
                    <measurement group_id="O2" value="20.302" lower_limit="-280.86" upper_limit="185.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 36 hours, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.397" lower_limit="-440.47" upper_limit="238.01"/>
                    <measurement group_id="O2" value="56.970" lower_limit="-265.30" upper_limit="289.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 42 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.538" lower_limit="-430.69" upper_limit="356.89"/>
                    <measurement group_id="O2" value="15.815" lower_limit="-250.52" upper_limit="200.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 48 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.700" lower_limit="-150.90" upper_limit="90.51"/>
                    <measurement group_id="O2" value="49.802" lower_limit="-279.51" upper_limit="181.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 60 hours, n=6, 5,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-104.425" lower_limit="-273.75" upper_limit="23.96"/>
                    <measurement group_id="O2" value="25.040" lower_limit="-208.52" upper_limit="406.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 72 hours, n=6, 6,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.737" lower_limit="-436.82" upper_limit="339.54"/>
                    <measurement group_id="O2" value="90.590" lower_limit="-155.63" upper_limit="272.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)</title>
        <description>Blood samples were collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK. Baseline was the average of all pre-dose measurements (Day -1 [pre-dose at 16 hours, 14 hours, 12 hours and 10 hours] and Day 1 [pre-dose at 30 minutes and 2 hours]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
        <time_frame>Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose</time_frame>
        <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Cohort 3: Placebo</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 matching placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
            <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Cohort 6: GSK335065 12 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Cohort 7: GSK335065 35 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
          </group>
          <group group_id="O7">
            <title>Part A-Cohort 8: GSK335065 54 mg</title>
            <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)</title>
          <description>Blood samples were collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK. Baseline was the average of all pre-dose measurements (Day -1 [pre-dose at 16 hours, 14 hours, 12 hours and 10 hours] and Day 1 [pre-dose at 30 minutes and 2 hours]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.</description>
          <population>All Subject Population. Data was not collected for Cohorts 4 to 8 as no participants were enrolled. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Arbitrary units</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3HK, 6 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" lower_limit="0.049" upper_limit="0.049"/>
                    <measurement group_id="O2" value="0.133" lower_limit="0.133" upper_limit="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 15 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.233" lower_limit="0.233" upper_limit="0.233"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.168" lower_limit="0.168" upper_limit="0.168"/>
                    <measurement group_id="O2" value="-0.823" lower_limit="-0.823" upper_limit="-0.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.351" lower_limit="-0.351" upper_limit="-0.351"/>
                    <measurement group_id="O2" value="-0.784" lower_limit="-0.784" upper_limit="-0.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.380" lower_limit="-0.380" upper_limit="-0.380"/>
                    <measurement group_id="O2" value="-0.337" lower_limit="-0.337" upper_limit="-0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.396" lower_limit="-0.396" upper_limit="-0.396"/>
                    <measurement group_id="O2" value="-0.255" lower_limit="-0.255" upper_limit="-0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.058" lower_limit="-0.058" upper_limit="-0.058"/>
                    <measurement group_id="O2" value="-0.378" lower_limit="-0.378" upper_limit="-0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 4.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.581" lower_limit="-0.581" upper_limit="-0.581"/>
                    <measurement group_id="O2" value="-0.339" lower_limit="-0.339" upper_limit="-0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" lower_limit="0.164" upper_limit="0.164"/>
                    <measurement group_id="O2" value="-0.304" lower_limit="-0.304" upper_limit="-0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 9 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.607" lower_limit="0.607" upper_limit="0.607"/>
                    <measurement group_id="O2" value="-0.935" lower_limit="-0.935" upper_limit="-0.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.070" lower_limit="0.070" upper_limit="0.070"/>
                    <measurement group_id="O2" value="-0.495" lower_limit="-0.495" upper_limit="-0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 15 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" lower_limit="0.076" upper_limit="0.076"/>
                    <measurement group_id="O2" value="-0.220" lower_limit="-0.220" upper_limit="-0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 18 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" lower_limit="0.101" upper_limit="0.101"/>
                    <measurement group_id="O2" value="-0.231" lower_limit="-0.231" upper_limit="-0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.088" lower_limit="-0.088" upper_limit="-0.088"/>
                    <measurement group_id="O2" value="-0.149" lower_limit="-0.149" upper_limit="-0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 30 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" lower_limit="0.178" upper_limit="0.178"/>
                    <measurement group_id="O2" value="-0.284" lower_limit="-0.284" upper_limit="-0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039" lower_limit="-0.039" upper_limit="-0.039"/>
                    <measurement group_id="O2" value="-0.172" lower_limit="-0.172" upper_limit="-0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 42 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" lower_limit="0.206" upper_limit="0.206"/>
                    <measurement group_id="O2" value="-0.035" lower_limit="-0.035" upper_limit="-0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.331" lower_limit="0.331" upper_limit="0.331"/>
                    <measurement group_id="O2" value="0.004" lower_limit="0.004" upper_limit="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 60 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="0.004" upper_limit="0.004"/>
                    <measurement group_id="O2" value="-0.090" lower_limit="-0.090" upper_limit="-0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" lower_limit="0.496" upper_limit="0.496"/>
                    <measurement group_id="O2" value="0.397" lower_limit="0.397" upper_limit="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 84 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" lower_limit="0.146" upper_limit="0.146"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.002" upper_limit="-0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.402" lower_limit="0.402" upper_limit="0.402"/>
                    <measurement group_id="O2" value="0.418" lower_limit="0.418" upper_limit="0.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 108 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.122" lower_limit="-0.122" upper_limit="-0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.318" lower_limit="0.318" upper_limit="0.318"/>
                    <measurement group_id="O2" value="0.682" lower_limit="0.682" upper_limit="0.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 132 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.231" lower_limit="-0.231" upper_limit="-0.231"/>
                    <measurement group_id="O2" value="-0.488" lower_limit="-0.488" upper_limit="-0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.381" lower_limit="0.381" upper_limit="0.381"/>
                    <measurement group_id="O2" value="0.301" lower_limit="0.301" upper_limit="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 156 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" lower_limit="-0.024" upper_limit="-0.024"/>
                    <measurement group_id="O2" value="0.413" lower_limit="0.413" upper_limit="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3HK, 168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" lower_limit="0.203" upper_limit="0.203"/>
                    <measurement group_id="O2" value="1.442" lower_limit="1.442" upper_limit="1.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 6 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.77" lower_limit="32.77" upper_limit="32.77"/>
                    <measurement group_id="O2" value="60.96" lower_limit="60.96" upper_limit="60.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 15 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.51" lower_limit="23.51" upper_limit="23.51"/>
                    <measurement group_id="O2" value="109.14" lower_limit="109.14" upper_limit="109.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.63" lower_limit="29.63" upper_limit="29.63"/>
                    <measurement group_id="O2" value="175.50" lower_limit="175.50" upper_limit="175.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.97" lower_limit="-11.97" upper_limit="-11.97"/>
                    <measurement group_id="O2" value="51.83" lower_limit="51.83" upper_limit="51.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.29" lower_limit="-11.29" upper_limit="-11.29"/>
                    <measurement group_id="O2" value="256.80" lower_limit="256.80" upper_limit="256.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.46" lower_limit="-63.46" upper_limit="-63.46"/>
                    <measurement group_id="O2" value="238.54" lower_limit="238.54" upper_limit="238.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.88" lower_limit="121.88" upper_limit="121.88"/>
                    <measurement group_id="O2" value="296.10" lower_limit="296.10" upper_limit="296.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 4.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" lower_limit="9.92" upper_limit="9.92"/>
                    <measurement group_id="O2" value="251.86" lower_limit="251.86" upper_limit="251.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" lower_limit="-3.33" upper_limit="-3.33"/>
                    <measurement group_id="O2" value="357.65" lower_limit="357.65" upper_limit="357.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 9 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.10" lower_limit="34.10" upper_limit="34.10"/>
                    <measurement group_id="O2" value="-97.16" lower_limit="-97.16" upper_limit="-97.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.83" lower_limit="15.83" upper_limit="15.83"/>
                    <measurement group_id="O2" value="19.56" lower_limit="19.56" upper_limit="19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 15 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.38" lower_limit="23.38" upper_limit="23.38"/>
                    <measurement group_id="O2" value="220.24" lower_limit="220.24" upper_limit="220.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 18 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.01" lower_limit="15.01" upper_limit="15.01"/>
                    <measurement group_id="O2" value="200.28" lower_limit="200.28" upper_limit="200.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" lower_limit="6.46" upper_limit="6.46"/>
                    <measurement group_id="O2" value="270.82" lower_limit="270.82" upper_limit="270.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 30 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="3.36" upper_limit="3.36"/>
                    <measurement group_id="O2" value="250.63" lower_limit="250.63" upper_limit="250.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.66" lower_limit="69.66" upper_limit="69.66"/>
                    <measurement group_id="O2" value="242.45" lower_limit="242.45" upper_limit="242.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 42 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.27" lower_limit="44.27" upper_limit="44.27"/>
                    <measurement group_id="O2" value="181.50" lower_limit="181.50" upper_limit="181.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.83" lower_limit="45.83" upper_limit="45.83"/>
                    <measurement group_id="O2" value="185.08" lower_limit="185.08" upper_limit="185.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 60 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.48" lower_limit="18.48" upper_limit="18.48"/>
                    <measurement group_id="O2" value="133.60" lower_limit="133.60" upper_limit="133.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.49" lower_limit="47.49" upper_limit="47.49"/>
                    <measurement group_id="O2" value="148.38" lower_limit="148.38" upper_limit="148.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 84 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" lower_limit="11.04" upper_limit="11.04"/>
                    <measurement group_id="O2" value="102.65" lower_limit="102.65" upper_limit="102.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.42" lower_limit="30.42" upper_limit="30.42"/>
                    <measurement group_id="O2" value="116.33" lower_limit="116.33" upper_limit="116.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 108 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.09" lower_limit="1.09" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.15" lower_limit="39.15" upper_limit="39.15"/>
                    <measurement group_id="O2" value="114.69" lower_limit="114.69" upper_limit="114.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 132 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.46" lower_limit="-63.46" upper_limit="-63.46"/>
                    <measurement group_id="O2" value="46.58" lower_limit="46.58" upper_limit="46.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.70" lower_limit="27.70" upper_limit="27.70"/>
                    <measurement group_id="O2" value="138.24" lower_limit="138.24" upper_limit="138.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 156 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.46" lower_limit="16.46" upper_limit="16.46"/>
                    <measurement group_id="O2" value="89.25" lower_limit="89.25" upper_limit="89.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kyn, 168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.94" lower_limit="18.94" upper_limit="18.94"/>
                    <measurement group_id="O2" value="73.34" lower_limit="73.34" upper_limit="73.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Tryptophan Metabolites-Part B</title>
        <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)</time_frame>
        <population>All Subject Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
            <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Tryptophan Metabolites-Part B</title>
          <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
          <population>All Subject Population. Data was not collected as no participants were enrolled in Part B of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Tryptophan Metabolites-Part C</title>
        <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
        <time_frame>Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)</time_frame>
        <population>All Subject Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Placebo</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C-Cohort 13: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
          </group>
          <group group_id="O3">
            <title>Part C-Cohort 14: GSK3335065</title>
            <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Tryptophan Metabolites-Part C</title>
          <description>Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.</description>
          <population>All Subject Population. Data was not collected as no participants were enrolled in Part C of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and serious adverse events (SAEs) were collected from admission until follow-up (Up to Day 22) for Part A (Cohorts 1 to 3).</time_frame>
      <desc>AEs and SAEs were not collected for Part A (Cohorts 4 to 8) and Parts B and C as no participants were enrolled due to termination of the study during Part A-Cohort 3. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Healthy male participants were administered a single intravenous (IV) bolus dose of GSK3335065 matching placebo on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part A-Cohort 1: GSK3335065 0.1 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.1 milligram (mg) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part A-Cohort 2: GSK3335065 0.25 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 0.25 mg on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part A-Cohort 3: GSK3335065 1.3 mg</title>
          <description>Healthy male participants were administered a single IV bolus dose of GSK3335065 1.3 mg on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part A-Cohort 4: GSK335065 2.6 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 2.6 mg.</description>
        </group>
        <group group_id="E6">
          <title>Part A-Cohort 5: GSK335065 5.5 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 5.5 mg.</description>
        </group>
        <group group_id="E7">
          <title>Part A-Cohort 6: GSK335065 12 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 12 mg.</description>
        </group>
        <group group_id="E8">
          <title>Part A-Cohort 7: GSK335065 35 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 35 mg.</description>
        </group>
        <group group_id="E9">
          <title>Part A-Cohort 8: GSK335065 54 mg</title>
          <description>Healthy male participants were planned to be administered a single IV bolus dose of GSK335065 54 mg.</description>
        </group>
        <group group_id="E10">
          <title>Part B: Placebo</title>
          <description>Healthy male participants were planned to be administered IV bolus dose of placebo on Day 1 followed by continuous IV infusion of placebo for 7 days.</description>
        </group>
        <group group_id="E11">
          <title>Part B-Cohort 9: 0.14mg IV Bolus+0.012 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered an IV bolus dose of GSK3335065 0.14 mg on Day 1 followed by continuous IV infusion of GSK3335065 0.012 mg/ hour for 7 days.</description>
        </group>
        <group group_id="E12">
          <title>Part B-Cohort 10: 7.5 mg IV Bolus+0.63 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 7.5 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 0.63 mg/hour for 7 days.</description>
        </group>
        <group group_id="E13">
          <title>Part B-Cohort 11: 12 mg IV Bolus+1.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 12 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 1.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="E14">
          <title>Part B-Cohort 12: 23 mg IV Bolus Dose+2.1 mg/Hour IV Infusion</title>
          <description>Participants were planned to be administered IV bolus dose of GSK3335065 23 mg on Day 1 followed by continuous IV infusion of GSK3335065 at a dose of 2.1 mg/hour for 7 days.</description>
        </group>
        <group group_id="E15">
          <title>Part C: Placebo</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered either a single intravenous dose of placebo or repeat doses of placebo as continuous infusion over 7 days.</description>
        </group>
        <group group_id="E16">
          <title>Part C-Cohort 13: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered a single intravenous dose of GSK3335065.</description>
        </group>
        <group group_id="E17">
          <title>Part C-Cohort 14: GSK3335065</title>
          <description>Part C was planned to be conducted in women of non-child bearing potential. Participants were planned to be administered repeat doses of GSK3335065 as continuous IV infusion over 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to sample handling errors at clinical site, reported results (3HK/Kyn) in Cohort 3 are characterized by a consistent negative bias; therefore must not be compared with concentration data from Cohort 1 or 2.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03245619
org study id: 201570
secondary id: 2016-001303-22
nct id: NCT03245619
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of
      reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them
      at this level throughout the treatment period. This study will utilize an adaptive design and
      is divided into 3 parts. Part A will consist of 8 cohorts (1-8) and is Single Ascending Dose
      (SAD) of GSK3335065 by IV bolus in males. Part B will be initiated after completion of dosing
      in Part A. It will involve ascending IV bolus doses of GSK3335065 followed by IV constant
      infusion for 7 days in males and will consist of four cohorts (9-12). Part C consists of a
      single dose of GSK3335065 by IV bolus (cohort 13), and a single dose followed by continuous
      infusion over 7 days (cohort 14) in females of non-child bearing potential (WONCBP). Total 64
      subjects will be evaluated in the study of which Part A will include 16 healthy male
      subjects, Part B will include 32 healthy male subjects and Part C will include 16 WONCBP. In
      Part A, cohorts 1 and 2 will last up to 19 weeks and cohorts 3 to 8 will last up to 7 weeks
      and Part B will last up to 13 weeks. In Part C cohort 7 will last up to 7 weeks and cohort 8
      will last for 13 weeks.
allocation: Randomized
intervention model: Sequential Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A
time frame: Up to Day 22
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. All Subject Population comprised of all participants randomized to treatment who received at least one dose of study treatment. AEs and SAEs were collected from admission until follow-up. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With AEs and SAEs-Part B
time frame: Up to Day 34
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.
measure: Number of Participants With AEs and SAEs-Part C
time frame: Up to Day 34
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.
measure: Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A
time frame: Up to Day 22
description: Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: >0.54 proportion of red blood cells in blood); hemoglobin (high: >180 grams per liter [g/L]), lymphocytes (low: <0.8x10^9 cells per liter [cells/L]); neutrophil count (low: <1.5x10^9 cells/L); platelet count (low: <100x10^9 cells/L and high: >550x10^9 cells/L); white blood cells count (low: <3x10^9 cells/L and high: >20x10^9 cells/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B
time frame: Up to Day 34
description: Blood samples were planned to be collected for the assessment of hematology parameters.
measure: Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C
time frame: Up to Day 34
description: Blood samples were planned to be collected for the assessment of hematology parameters.
measure: Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A
time frame: Up to Day 22
description: Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: albumin (low: <30 millimoles per liter [mmol/L]); alanine aminotransferase (ALT) (high: >=2xupper limit of normal [ULN]); aspartate aminotransferase (AST) (high: >=2xULN); alkaline phosphatase (ALP) (high: >=2xULN); total bilirubin (high: >=1.5xULN); calcium (low: <2 mmol/L and high: >2.75 mmol/L); glucose (low: <3 mmol/L and high: >9 mmol/L); potassium (low: <3 mmol/L and high: >5.5 mmol/L) and sodium (low: <130 mmol/L and high: >150 mmol/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B
time frame: Up to Day 34
description: Blood samples were planned to be collected for the assessment of clinical chemistry parameters.
measure: Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C
time frame: Up to Day 34
description: Blood samples were planned to be collected for the assessment of clinical chemistry parameters.
measure: Number of Participants With Abnormal Urine Parameters-Part A
time frame: Up to Day 22
description: Urine samples were taken for the assessment of following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed and collected for any abnormal dipstick results. Number of participants with abnormal urine parameters any time post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With Abnormal Urine Parameters-Part B
time frame: Up to Day 34
description: Urine samples were planned to be collected for the assessment of urine parameters.
measure: Number of Participants With Abnormal Urine Parameters-Part C
time frame: Up to Day 34
description: Urine samples were planned to be collected for the assessment of urine parameters.
measure: Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A
time frame: Up to Day 22
description: Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QT interval corrected using Fridericia's formula (QTcF) and Bazett's QT interval corrected for heart rate (QTcB). ECG measurements were preceded by at least 5 minutes rest for the participant in a semi-recumbent position. Number of participants with abnormal-clinically significant and abnormal-not clinically significant ECG findings at worst case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With Abnormal ECG Findings-Part B
time frame: Up to Day 34
description: Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.
measure: Number of Participants With Abnormal ECG Findings-Part C
time frame: Up to Day 34
description: Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.
measure: Number of Participants With Abnormal Vital Signs-Part A
time frame: Up to Day 22
description: Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, respiration rate and temperature were measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Participants are counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Data for worst case post-Baseline relative to Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
measure: Number of Participants With Abnormal Vital Signs-Part B
time frame: Up to Day 34
description: Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.
measure: Number of Participants With Abnormal Vital Signs-Part C
time frame: Up to Day 34
description: Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.
measure: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for pharmacokinetic (PK) analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. PK Parameter Population comprised of all active participants whose PK sample was obtained and analyzed and who provided PK parameters.
measure: AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: AUC(0-t) for GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: AUC(0-t) for GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: AUC(0-t) for GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
measure: AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: AUC(0-Inf) for GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: AUC(0-Inf) for GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: AUC(0-Inf) for GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Tlast of GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Tlast of GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Tlast of GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Tlast of GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Cmax of GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Cmax of GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Cmax of GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Cmax of GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Tmax of GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Tmax of GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Tmax of GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Tmax of GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Clearance for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
measure: Clearance for GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Clearance for GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Clearance for GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Clearance for GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
measure: Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: Volume of Distribution for GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Volume of Distribution for GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Volume of Distribution for GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
measure: T1/2 for GSK3335065-Part A (Cohorts 3 to 8)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
measure: T1/2 for GSK3335065-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: T1/2 for GSK3335065-Part C (Cohort 13)
time frame: 1 hour pre-dose, 6, 12, 15, 20, and 30 minutes, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: T1/2 for GSK3335065-Part C (Cohort 14)
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18hours post-infusion), Days2 to 7 (pre-dose), Day8 (end of infusion, 6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-infusion)
description: Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
measure: Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)
time frame: Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60 and 72 hours post-dose
description: Blood samples were collected to measure the kynurenine-3-monooxygenase (KMO) enzyme inhibition by determining the levels of the biomarkers Kynurenine (Kyn) and 3-hydroxykynurenine (3-HK). Baseline was the average of all pre-dose measurements (Day 1 [pre-dose at 1 hour and 30 minutes]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.
measure: Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)
time frame: Baseline, 6, 15 and 30 minutes, 1, 1.5, 2, 3, 4.5, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 and 168 hours post-dose
description: Blood samples were collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK. Baseline was the average of all pre-dose measurements (Day -1 [pre-dose at 16 hours, 14 hours, 12 hours and 10 hours] and Day 1 [pre-dose at 30 minutes and 2 hours]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.
measure: Change From Baseline in Levels of Tryptophan Metabolites-Part B
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)
description: Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.
measure: Change From Baseline in Levels of Tryptophan Metabolites-Part C
time frame: Day1 (Pre-dose, 6, 15, 30 minutes, 1, 2, 3, 4.5, 6, 9, 12, 18 hours post-infusion), Days2 to 7 (pre-dose), Day8 (6 and 12 hours post-infusion), Day9 (18, 24, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 and 180 hours post-infusion)
description: Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.
arm group label: Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A
arm group type: Experimental
description: Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
arm group label: Subjects receiving Placebo (Cohorts 1 to 8) in Part A
arm group type: Experimental
description: Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
arm group label: Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B
arm group type: Experimental
description: Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
arm group label: Subjects receiving Placebo (Cohort 9 to 12) in Part B
arm group type: Experimental
description: Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
arm group label: Subjects receiving GSK3335065 (Cohort 13) in Part C
arm group type: Experimental
description: WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
arm group label: Subjects receiving Placebo (Cohort 13) in Part C
arm group type: Experimental
description: WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
arm group label: Subjects receiving GSK3335065 (Cohort 14) in Part C
arm group type: Experimental
description: WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
arm group label: Subjects receiving Placebo (Cohort 14) in Part C
arm group type: Experimental
description: WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
intervention type: Drug
intervention name: GSK3335065
description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
arm group label: Subjects receiving GSK3335065 (Cohort 13) in Part C
arm group label: Subjects receiving GSK3335065 (Cohort 14) in Part C
arm group label: Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B
arm group label: Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A
intervention type: Drug
intervention name: Placebo
description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
arm group label: Subjects receiving Placebo (Cohort 13) in Part C
arm group label: Subjects receiving Placebo (Cohort 14) in Part C
arm group label: Subjects receiving Placebo (Cohort 9 to 12) in Part B
arm group label: Subjects receiving Placebo (Cohorts 1 to 8) in Part A
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Pancreatitis
mesh term: Pancreatitis, Acute Necrotizing
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
limitations and caveats: Due to sample handling errors at clinical site, reported results (3HK/Kyn) in Cohort 3 are characterized by a consistent negative bias; therefore must not be compared with concentration data from Cohort 1 or 2.
point of contact: 